Temporary Improvement in Activities of Daily Living After Steroid Therapy for the Treatment of Anti-Hu Antibody-Associated Syndrome in a Patient with Advanced Prostate Cancer

Yamaguchi, Takashi; Kamiya, Kohei; Izumi, Noriko; Hisanaga, Takayuki; Higashi, Kenjiro; Shima, Yasuo

doi:10.1016/j.jpainsymman.2010.10.254

Cited by 5 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of anti‐Hu antibodies does not preclude a cancer diagnosis . SCLC is the most commonly associated cancer, but many other malignancies have been reported, including breast cancer, ovarian cancer, Hodgkin lymphoma, transitional cell bladder cancer, prostate cancer, neuroendocrine tumors, malignant mixed Müllerian tumor, and sarcoma . SN precedes cancer diagnosis by a median interval of 3–8 months …”

Section: Specific Sensory Neuronopathiesmentioning

confidence: 99%

Sensory neuronopathies

Gwathmey

2015

Muscle and Nerve

View full text Add to dashboard Cite

The sensory neuronopathies (or ganglionopathies) are a small subcategory of neuropathies characterized by primary degeneration of the dorsal root ganglia and trigeminal ganglion sensory neurons, resulting in a distinctive clinical presentation. Patients typically have subacute onset of asymmetric, non-length-dependent sensory impairment and early ataxia. The etiologies of acquired sensory neuronopathies are rather limited. Early identification is imperative, as they may herald an underlying malignancy or an autoimmune condition such as Sjögren syndrome. This review addresses the various causes of acquired sensory neuronopathies, the recommended diagnostic approach, and treatment options. Finally, I will briefly discuss a select few hereditary and degenerative sensory neuronopathies, which, in contrast to the acquired disorders, are slowly progressive and are usually associated with additional neurological symptoms.

show abstract

Section: Specific Sensory Neuronopathiesmentioning

confidence: 99%

Sensory neuronopathies

Gwathmey

2015

Muscle and Nerve

View full text Add to dashboard Cite

show abstract

“…In the absence of large clinical trials, most therapeutic alternatives in patients with CNA‐antibodies derive from observational clinical studies and case reports . The usefulness of corticoids has been suggested in patients with anti‐Hu , anti‐Yo antibodies or in patients with PNS and without antibodies . Therapeutic effects of intravenous immunoglobulins (IVIg) appear to be limited, but in a very small proportion of patients with definite PNS (mainly with anti‐Hu or anti‐Yo antibodies) a favourable response has been described after IVIg therapy .…”

Section: Main Treatment Studies In Group 1 Antibodies: Antibodies Witmentioning

confidence: 99%

Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome

Honnorat

2014

Clin Exp Immunol

View full text Add to dashboard Cite

Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes

et al. 2016

View full text Add to dashboard Cite

Prostate cancer is the most common cancer among American and European men. Nervous system affection caused by local tumor growth or osseous metastases are the main causes of neurological symptoms in prostate cancer patients. Prostate cancer is rarely reported in association with paraneoplastic neurological syndromes (PNS). We have, therefore, studied clinical and paraclinical findings of a series of patients with prostate cancer and PNS, and reviewed cases reported in the literature. Case histories of 14 patients with definite PNS from the PNS Euronetwork database and from the authors' databases were reviewed. A PubMed literature search identified 23 patients with prostate cancer and PNS. Thus, a total of 37 case histories were reviewed with respect to syndrome type, cancer evolution, paraclinical investigations, antibody status, treatment and outcome. The three most frequent isolated PNS were paraneoplastic cerebellar degeneration, paraneoplastic encephalomyelitis (PEM)/limbic encephalitis and subacute sensory neuronopathy (SSN). Onconeural antibodies were detected in 23 patients, in most cases the Hu antibody (17 patients, 74 % of all antibody-positive cases). Other well-characterized onconeural antibodies (Yo, CV2/CRMP5, amphiphysin, VGCC antibodies) were found in a minority. PNS was diagnosed prior to prostate cancer diagnosis in 50 % of the cases. The association of PNS with prostate cancer is quite infrequent, but clinically important. PNS often heralds prostate cancer diagnosis. Syndromes associated with Hu antibodies predominate. Another tumor more prone to associate with PNS should always be excluded.

show abstract

Temporary Improvement in Activities of Daily Living After Steroid Therapy for the Treatment of Anti-Hu Antibody-Associated Syndrome in a Patient with Advanced Prostate Cancer

Cited by 5 publications

References 13 publications

Sensory neuronopathies

Sensory neuronopathies

Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome

Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes

Contact Info

Product

Resources

About